Content Detail

• Content META

  Title	Precipio Achieves Key Q4-2024 Financial Goals: Positive Adjusted EBITDA and Positive Cash Flow (unaudited)
  ID	7267956
  External ID	7579123076
  Author	Unknown
  Published Date	Feb. 25, 2025, 9:23 a.m.
  Summary	Both metrics demonstrate the ability to achieve financial independence NEW HAVEN, Conn., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , announc
  Tags	press-release
  URL	https://www.einpresswire.com/article/789026927/precipio-achieves-key-q4-2024-financial-goals-positive-adjusted-ebitda-and-positive-cash-flow-unaudited
  Sentiment	Negative: 0.01752    Neutral: 0.03738    Positive: 0.94509
  Relevance	0.02335

• Content Details

  Content ID	4573202
  Key	94ea507d-3a4f-4131-8fc4-2059c5e64fe0
  Content	Both metrics demonstrate the ability to achieve financial independence NEW HAVEN, Conn., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , announces that it has achieved two important financial goals in the last quarter of 2024: Positive Adjusted EBITDA – Precipio reports (unaudited) A djusted EBITDA of $0.4 M for Q4-2024. Adjusted EBITDA is a non-GAAP metric that comprises EBITDA, less non-cash stock-based compensation expense and other significant or non-operating (income) or expenses. Please see a detailed explanation at the bottom of this press release. Positive Cash flow. Precipio reports an (unaudited) increase of $0.3M in cash during Q4-2024. Of this improvement, $75,000 was due to directors' fees paid in stock; the balance is cash flow from operations. The combination of these two factors demonstrates the Company's ability to achieve and sustain financial independence by generating enough positive cash flow from its pathology service division to fund ongoing R&D as well as continued, consistent investment in growing the high value product business. Management notes that the financial performance in future quarters may fluctuate from positive to negative due to various factors. One such occurrence may occur in Q1 when pathology business revenues and cash receipts are typically reduced by renewed insurance deductibles. Prior years' experience indicates operating results will not be affected by these factors nearly as much in Q2. However, with the Company's current cash reserves and growth pipeline, management believes it is on track to turn the corner and become a profitable company. “Ending 2024 with these financial results is an important step for our company. While we may still face the ups and downs as we grow the business, it is evident that our company can translate business growth into positive financial outcomes, and build the value its shareholders deserve to have,” said Ilan Danieli, CEO. “Managing a company that no longer relies on outside capital infusions for its survival enables us to make decisions based on growth and value creation without the constraints imposed by cash conservation concerns. We can focus on building capabilities and channeling them towards developing our products and growing the business. We are on track to have an exciting year for our company.” EBITDA and Adjusted EBITDA Reconciliation and Explanation EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is a non-GAAP financial measure that is widely used to evaluate operational performance and pre-tax profitability. Management believes Adjusted EBITDA provides investors with a useful perspective on the company's financial health, particularly where non-cash amortization has an important impact on profitability. Adjusted EBITDA as we define it will also exclude the non-cash costs of employee stock options and unusual, one-time costs. This is the first time we are reporting Adjusted EBITDA and we intend to continue reporting it in future quarters. Below is a reconciliation of Net Income, EBITDA and Adjusted EBITDA for the fourth quarter of 2024: ($ in millions, unaudited) Net income/(loss) (GAAP) A djustments to net income/(loss): Interest expense, net Income taxes Depreciation Amortization of intangibles EBITDA (non-GAAP) Further Adjustments to EBITDA Stock-based compensation expense Other significant (income) expenses Adjusted EBITDA (non-GAAP) About Precipio Precipio is a healthcare biotechnology company focused on cancer diagnostics. Our mission is to address the pervasive problem of cancer misdiagnoses by developing solutions in the form of diagnostic products and services. Our products and services deliver higher accuracy, improved laboratory workflow, and ultimately better patient outcomes, which reduce healthcare expenses. Precipio develops innovative technologies in our laboratory where we design, test, validate, and use these products clinically, improving diagnostic outcomes. Precipio then commercializes these technologies as proprietary products that serve the global laboratory community and further scales Precipio's reach to eradicate misdiagnosis. Availability of Other Information About Precipio For more information, please visit the Precipio website at https://www.precipiodx.com/ or follow Precipio on X (formerly Twitter) ( @PrecipioDx ) and LinkedIn (Precipio) and on Facebook . Investors and others should note that we communicate with our investors and the public using our company website ( https://www.precipiodx.com ), including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X and LinkedIn. The information that we post on our website or on X or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended. Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the targets set herein and related timing. Except for historical information, statements about future volumes, sales, growth, costs, cost savings, margins, earnings, earnings per share, diluted earnings per share, cash flows, adjusted EBITDA, plans, objectives, expectations, growth or profitability and our potential to reach financial independence are forward-looking statements based on management's estimates, beliefs, assumptions and projections. Words such as “could,” “may,” “expects,” “anticipates,” “will,” “targets,” “goals,” “projects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “predicts,” and variations on such words, and similar expressions that reflect our current views with respect to future events and operational, economic and financial performance, are intended to identify such forward-looking statements. These forward-looking statements are only predictions based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and our other reports filed with the U.S. Securities and Exchange Commission. Any such forward-looking statements represent management's estimates as of the date of this press release only. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release. Inquiries: investors@precipiodx.com +1-203-787-7888 Ext. 523 Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
  Content Reference URL	None

• Publisher

  Publisher Name	Alternative Emerging Investor (#5251)
  Publisher URL	https://www.einpresswire.com
  Description	None
  Trust Flow Score	40
  Citation Flow Score	47

• Data Source

  Data Source Name	Quantexa News (#5)
  Data Source Type	news
  Data Source URL	https://app.aylien.com/dashboard
  Description	Welcome to Quantexa News API — the most powerful way to aggregate, filter, and integrate global news data into your apps and models.
  Weight	10